Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Zevra Therapeutics and keeping the price target at $25.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Zevra Therapeutics’ promising prospects. The recent presentation of positive data for Miplyffa at the International Congress of Inborn Errors of Metabolism (ICIEM) underscores the drug’s consistent safety and efficacy profile in treating Niemann-Pick disease type C (NPC). This positive data, combined with the early revenue generation and patient enrollment figures, indicates strong market uptake and potential for further growth.
Additionally, the recent marketing authorization application (MAA) filing with the European Medicines Agency (EMA) presents a significant opportunity for Zevra to expand its market presence into Europe. The valuation model for Zevra incorporates risk adjustments for their various products, with Miplyffa receiving a lower risk adjustment due to its commercial and reimbursement potential. These factors, along with a calculated 12-month price target of $25, contribute to McCarthy’s optimistic outlook and Buy rating for the stock.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZVRA in relation to earlier this year.